Skip directly to content

Guías Internacionales de Manejo

Guias Internacionales de Manejo de Neuropatia Diabetica Dolorosa indican el uso de Lyrica con tratamiento de primera linea.1-7


 

Las guías soportan el uso de LYRICA como un tratamiento de primera línea con evidencia nivel A 1

Referencias:

  1. Pop-Busui R. Boulton AJM. Feldman EL, et al Diabetic neuropathy. A position statement by the American Diabetes Association. Diabetes Care 2017;40:136-154
  2. Dworkin RH, O’Connor AB, Audette J, et al, Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2010;85(3)(suppl);S3-S14.
  3. Bril V. England J, Franklin GM, et al. Evidence-bases guideline: Tratment of painful diabetic neuropathy; report of the American Academy of Neurology, the Amercian Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation . Neurology 2011:76:1758-1765
  4. Moulin DE, Boulanger A. Clark AJ, et al. Pharmacological management of chronic neuropathic pain; Revised consensus statement from Canadian Pain Society. Pain Res Manage 2014;19(6)328-335
  5. Finnerup NB, Attal N, Haroutounian S. et aL Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015:14:162-173.
  6. Attal N. Cruccu G. Baron R. et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010:17:1113-1123
  7. D’Arcy Y, McCarberg B, Parsons B, Behar R, Thorpe A, Alexander A. Pregabalin for the treatment of neuropathic pain: a narrative review for primary care providers. Curr Med Res Opin 2017;33(8):1353-1359
  8. Documento local de producto Lyrica 25mg, 75mg y 150 mg: LLD_Per_Japón_01Feb2017_v2.0 y Documento local deproducto Lyrica 300 mg: LLD_Per_USPI_09Marzo2016_v1.0

 

Código Interno: PP-LYR-PEB-0027

Volver a menú